Physicians' Academy for Cardiovascular Education
Patients with recent MI were at higher risk of CV events and tended to have greater ARRs with evolocumab compared to those with remote MIs, as shown in this secondary analysis of the FOURIER trial.
Survival was examined in a cohort of hospitalized COVID-19 patients in New York City, who were divided in those who received anticoagulation during hospital stay and those who did not.
Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the effect of Lp(a) on CV outcomes.
This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.
Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.
Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and ARBs in patients with COVID-19. All three studies showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19.
Benjamin Peterson gives a brief presentation of the results of the REDUCE-IT REVASC study, which evaluated the effect of icosapent ethyl on first and total revascularizations in patients with hypertriglyceridemia.
The PCSK9 inhibitor evolocumab significantly reduced risk of MI across multiple MI subtypes and sizes, as shown by an analysis of the FOURIER trial.
Administration of 4 g/day icosapent ethyl reduced first coronary revascularizations by 34% compared to placebo in patients with elevated triglyceride levels, who had CVD or diabetes with additional CV risk factors.
A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.
This comment article describes characteristics of coagulopathy in patients with COVID-19 and discusses recommendations for the therapeutic management of COVID-19-associated coagulopathy.
A large Norwegian cohort study showed that drinking filtered coffee was associated with lower mortality than no coffee, while no association between coffee drinking and mortality was observed for those drinking unfiltered coffee.
